---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-264658"
form_type: "8-K"
ticker: "SLNO"
cik: "0001484565"
company_name: "SOLENO THERAPEUTICS INC"
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:36:04.024633+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Soleno reports Q3 net income $26M, first profitable quarter; VYKAT XR revenue $66M

## Summary
- Product revenue of $66.0M from VYKAT XR launch (first revenue, vs $0 prior year); net income $26.0M ($0.47 diluted EPS) vs net loss of $76.6M in Q3 2024.
- 1,043 patient start forms and 764 active patients on VYKAT XR as of Sept 30, 2025; 494 unique prescribers and over 132M lives covered since March approval.
- Cash and securities at $556.1M, including $230M gross proceeds from July common stock offering; operating cash flow of $43.5M in Q3.
- Sequential product revenue more than doubled from $32.7M in Q2 2025; R&D expense fell to $8.4M from $30.1M, and SG&A to $33.8M from $49.2M.
- Appointed Mark W. Hahn to Board of Directors and Audit Committee; contingent consideration liability for Essentialis earnout estimated at $19.5M.

## SEC filing metadata
- accession: 0001193125-25-264658
- form_type: 8-K
- ticker: SLNO
- cik: 0001484565
- company_name: SOLENO THERAPEUTICS INC
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1484565/000119312525264658/0001193125-25-264658-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1484565/000119312525264658/d58763d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-264658
- JSON: https://secwatch.observer/filing/0001193125-25-264658.json
- Plain text: https://secwatch.observer/filing/0001193125-25-264658.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.